Apimeds Pharmaceuticals US, Inc. reported an inability to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, on time due to ongoing audit preparations. The company expects to file it by April 30, 2026, and acknowledges potential non-compliance with NYSE listing requirements.